|

Standard lymphodepletion regimen Clinical Trials

3 actively recruiting trials across 2 locations

No change since June 2026

Also known as: Bendamustine, Cyclophosphamide, Fludarabine

Pipeline

Phase 1: 2Phase 2/3: 1

Top Sponsors

  • Stanford University1
  • Kyverna Therapeutics1
  • Arcellx, Inc.1

Indications

  • Myasthenia Gravis2
  • Cancer2
  • Multiple Sclerosis, Secondary Progressive1
  • Multiple Sclerosis, Primary Progressive1
  • Autoimmune1

Los Angeles, California2 trials

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

UCLA Medical Center

Phase 1
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Ronald Reagan UCLA Medical Center

Phase 2/3

Palo Alto, California1 trial

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Stanford Multiple Sclerosis Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.